Tumor Immunology Overview

Principles

Definition

Tumor immunology is a specialized field of biomedical research focused on understanding the intricate interactions between the host immune system and developing or established malignant tumors. This discipline investigates how the immune system recognizes, attempts to eliminate, or is suppressed and evaded by cancer cells, providing critical insights for the development of cancer immunotherapies.

Ontological type

Tumor Immune Evasion

Immunotherapy Modalities

Immune Surveillance Mechanisms

Key developments

Key Figures

T Cell Foundations era

James P. Allison [1] is a prominent figure associated with Stanford University [3] and The University of Texas Southwestern Medical Center [4] during the T Cell Foundations era. His key contribution in this era was pioneering immune checkpoint blockade via CTLA-4, as detailed in the paper 'Enhancement of Antitumor Immunity by CTLA-4 Blockade' [7], which demonstrated that releasing inhibitory brakes on T cells could enhance anti-tumor immunity. Michael T. Lotze [2] has affiliations with La Roche College [5] and Johns Hopkins University [6] during this era. His work laid foundational immunotherapy concepts by showing that tumor-infiltrating lymphocytes combined with interleukin-2 could mediate responses in patients, as described in 'Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma' [8] and 'Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study' [9], highlighting a tumor-specific adoptive approach enabled by IL-2 that shaped subsequent T cell therapies.

Antigen Presentation and Vaccines era

Steven A. Rosenberg [1] conducted pivotal work across Stanford University [3] and the University of Pennsylvania [4] during the Antigen Presentation and Vaccines era. His key contributions advanced cancer immunotherapy strategies, including vaccine concepts and T cell–mediated approaches, as illustrated by Cancer immunotherapy: moving beyond current vaccines [7], Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer [8], and gp100/pmel17 Is a Murine Tumor Rejection Antigen: Induction of 'Self'-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand [9]. Wolf H. Fridman [2] conducted influential work across Innsbruck Medical University [5] and Université Paris Cité [6] during this era. His contributions emphasized tumor immune contexture and cross-priming principles, as demonstrated by Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome [10], underscoring how immune infiltration informs prognosis and informs antigen presentation–based strategies.

Checkpoint-Driven Reprogramming era

Gad Getz [1] operated across Rockefeller University [3] and Harvard University [4] during the Checkpoint-Driven Reprogramming era. He contributed to the immunogenic personal neoantigen vaccine for patients with melanoma [6] and to defining T cell states associated with response to checkpoint immunotherapy in melanoma [7], advances that were pivotal for enabling antigen-specific vaccination and for mapping T cell phenotypes linked to durable responses in checkpoint-driven reprogramming. Eric S. Lander [2] has been active at Harvard University [4] and the Massachusetts Institute of Technology [5] during this era. He contributed to the immunogenic personal neoantigen vaccine for patients with melanoma [6], a genomics-guided approach that underscored the feasibility and potential of personalized cancer vaccines within checkpoint-driven reprogramming.